Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 3/2019

01-06-2019 | Breast Cancer | Epidemiology

Inflammatory and other breast cancer incidence rate trends by estrogen receptor status in the Surveillance, Epidemiology, and End Results database (2001–2015)

Authors: Sarah J. Aurit, Susan S. Devesa, Amr S. Soliman, Catherine Schairer

Published in: Breast Cancer Research and Treatment | Issue 3/2019

Login to get access

Abstract

Purpose

Inflammatory breast cancer (IBC) rates increased in the United States before the turn of the twenty-first century. We examine trends by estrogen receptor (ER) status since then.

Methods

Using data from the Surveillance, Epidemiology, and End Results (SEER) program for years 2001–2015, we calculated age-adjusted incidence rates for IBC (defined by AJCC TNM category T4d, extent of disease codes, and morphology code 8530) by ER status, which was imputed if unknown, among women aged 25–84 years. For comparison, we included other locally advanced breast cancer and other breast cancers partitioned into localized and regional/distant/unstaged. We fit joinpoint log-linear models to annual rates to calculate annual percentage change (APC) and average annual percentage change (AAPC).

Results

The rate of increase in ER+ IBC rates among women aged 25–44 (AAPC = 0.5) was similar to other advanced tumor types, but declines among women aged 45–84 (AAPC = − 2.2) were more rapid. Declines in ER− IBC rates for women aged 25–84 (AAPC = − 3.7) were more rapid than for other tumor types.

Conclusions

Our results show a reversal of the rising rates of IBC overall reported at the end of the twentieth century. Direction of trends for IBC is consistent with other breast cancer types, except for ER+ localized breast cancer in older women. Decreasing parity and rising prevalence of older age at first birth may contribute to declining rates of ER− IBC. Otherwise, patterns of changing risk factors are inconsistent with the trends we observed. Further studies of IBC are necessary to identify additional risk factors and possible preventive strategies.
Appendix
Available only for authorised users
Literature
1.
2.
Greene FL, Page DL, Fleming ID, Fritz AG, Balch CM, Haller DG et al (eds) (2002) AJCC cancer staging manual, 6th edn. Springer, New York
3.
Anderson WF, Chu KC, Chang S (2003) Inflammatory breast carcinoma and noninflammatory locally advanced breast carcinoma: distinct clinicopathologic entities? J Clin Oncol 21:2254–2259CrossRefPubMed
4.
Hance KW, Anderson WF, Devesa SS, Young HA, Levine PH (2005) Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute. J Natl Cancer Inst 97:966–975CrossRefPubMedPubMedCentral
5.
Chang S, Parker SL, Pham T, Buzdar AU, Hursting SD (1998) Inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program of the National Cancer Institute, 1975–1992. Cancer 82:2366–2372CrossRefPubMed
6.
Goldner B, Behrendt CE, Schoellhammer HF, Lee B, Chen SL (2014) Incidence of inflammatory breast cancer in women, 1992–2009, United States. Ann Surg Oncol 21:1267–1270CrossRefPubMed
7.
Hou N, Huo D (2013) A trend analysis of breast cancer incidence rates in the United States from 2000 to 2009 shows a recent increase. Breast Cancer Res Treat 138:633–641CrossRefPubMed
8.
Yeh ED, Jacene HA, Bellon JR, Nakhlis F, Birdwell RL, Georgian-Smith D, Giess CS, Hirshfield-Bartek J, Overmoyer B, Van den Abbeele AD (2013) What radiologists need to know about diagnosis and treatment of inflammatory breast cancer: a multidisciplinary approach. RadioGraphics 33:2003–2017CrossRefPubMed
9.
Beahrs OH, Carr DT, Rubin P (eds) (1977) Manual for staging of cancer, 1st edn. American Joint Committee for Cancer Staging and End Results Reporting, Chicago
10.
Beahrs OH, Myers MH (eds) (1983) Manual for staging of cancer, 2nd edn. J.B. Lippincott, Philadelphia
11.
Beahrs OH, Henson DE, Hutter RV, Myers MH (eds) (1988) Manual for staging of cancer, 3rd edn. J.B. Lippincott, Philadelphia
12.
Beahrs OH, Henson DE, Hutter RV, Kennedy BJ (eds) (1992) Manual for staging of cancer, 4th edn. J.B. Lippincott, Philadelphia
13.
Fleming ID, Cooper JS, Henson DE, Hutter RV, Kennedy BJ, Murphy GP et al (eds) (1997) AJCC cancer staging manual, 5th edn. Lippincott-Raven, Philadelphia
14.
Shambaugh EM, Gloeckler Ries L, Young JL, Kruse MA, Platz CE, Ryan RF et al (1988) SEER extent of disease 1988 codes and coding instructions. NIH, National Cancer Institute, Rockville
15.
16.
Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (eds) (2009) AJCC cancer staging manual, 7th edn. Springer, New York
17.
18.
Taylor SH, Walters R (2010) Potential impact of tumor registry rule changes for recording inflammatory breast cancer. Cancer 116(11 Suppl):2745–2747CrossRefPubMed
19.
20.
Chen T, Zhang N, Moran MS, Su P, Haffty BG, Yang Q. Borderline ER-positive primary breast cancer gains no significant survival benefit from endocrine therapy: a systematic review and meta-analysis (2017). Clinical Breast Cancer 18(1):1–8
21.
22.
Anderson WF, Katki HA, Rosenberg PS (2011) Incidence of breast cancer in the United States: current and future trends. J Natl Cancer Inst 103:1397–1402CrossRefPubMedPubMedCentral
23.
Howlander N, Chen VW, Ries LAG, Loch MM, Lee R, deSantis C, Lin CC, Ruhl J, Cronin KA (2014) Overview of breast cancer collaborative stage data items – their definitions, quality, usage, and clinical implications: a review of SEER data for 2004–2010. Cancer 120(23 suppl):3771–3780CrossRef
24.
Kim HJ, Fay MP, Feuer EJ, Midthune DN (2000) Permutation tests for joinpoint regression with applications to cancer rates. Stat Med 19:335–351 (correction: 2001;20:655)CrossRefPubMed
25.
Devesa SS, Donaldson J, Fears T (1995) Graphical representation of trends in rates. Am J Epidemiol 141:300–304CrossRefPubMed
26.
Toriola AT, Colditz GA (2013) Trends in breast cancer incidence and mortality in the United States: implications for prevention. Breast Cancer Res Treat 138:665–673CrossRefPubMed
27.
Clavel-Chapelon F, Gerber M (2002) Reproductive factors and breast cancer risk. Do they differ according to age at diagnosis? Breast Cancer Res Treat 72(2):107–115CrossRefPubMedPubMedCentral
28.
Althuis MD, Fergenbaum JH, Garcia-Closas M, Brinton LA, Madigan MP, Sherman ME (2004) Etiology of hormone receptor-defined breast cancer: a systematic review of the literature. Cancer Epideiol Biomark Prev 13(10):1558–1568
29.
Li CI, Beaber EF, Chen Tang M-T, Porter PL, Daling JR, Malone KE (2013) Reproductive factors and risk of estrogen receptor positive, triple negative, and HER2-neu overexpressing breast cancer among women 20–44 years of age. Breast Cancer Res Treat 137:579–587CrossRefPubMed
30.
Schairer C, Li Y, Frawley P, Graubard BI, Wellman RD, Buist DS, Kerlikowske K, Onega TL, Anderson WF, Miglioretti DL (2013) Risk factors for inflammatory breast cancer and other invasive breast cancers. J Natl Cancer Inst 105:1373–1384CrossRefPubMedPubMedCentral
31.
Kirmeyer SE, Hamilton BE (2011) Childbearing differences among three generations of U.S. women. NCHS Data Brief, p 68
32.
Finer LB, Philbin JM (2014) Trends in ages at key reproductive transitions in the United States, 1951–2010. Women’s Health Issues 24(3):e271–e279CrossRefPubMedPubMedCentral
33.
Munsell MF, Sprague BL, Berry DA, Chisholm G, Trentham-Dietz A (2014) Body mass index and breast cancer risk according to postmenopausal estrogen-progestin use and hormone receptor status. Epidemiol Rev 36:114–136CrossRefPubMedPubMedCentral
34.
An R, Xiang X (2016) Age-period-cohort analyses of obesity prevalence in US adults. Public Health 141:163–169CrossRefPubMed
35.
Schairer C, Gadalla SM, Pfeiffer RM, Moore SC, Engels EA (2017) Diabetes, abnormal glucose, dyslipidemia, hypertension and risk of inflammatory and other breast cancer. Cancer Epidemiol Biomark Prev 26:862–868CrossRef
36.
Menke A, Rust KF, Fradkin J, Cheng YJ. Cowie CC (2014) Associations between trends in race/ethnicity, aging, and body mass index with diabetes prevalence in the United States. Ann Intern Med 161:328–335CrossRefPubMed
Metadata
Title
Inflammatory and other breast cancer incidence rate trends by estrogen receptor status in the Surveillance, Epidemiology, and End Results database (2001–2015)
Authors
Sarah J. Aurit
Susan S. Devesa
Amr S. Soliman
Catherine Schairer
Publication date
01-06-2019
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 3/2019
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-019-05193-0

Other articles of this Issue 3/2019

Breast Cancer Research and Treatment 3/2019 Go to the issue

Epidemiology

Risk of ipsilateral breast tumor recurrence in primary invasive breast cancer following breast-conserving surgery with BRCA1 and BRCA2 mutation in China

Epidemiology

Quality of life in pre- and postmenopausal patients with early breast cancer: a comprehensive analysis from the prospective MaLife project

Brief Report

Clinical outcomes of breast leptomeningeal disease treated with intrathecal trastuzumab, intrathecal chemotherapy, or whole brain radiation therapy

Review

Applying a value-based care framework to post-mastectomy reconstruction

Epidemiology

Sentinel and non-sentinel lymph node metastases in patients with microinvasive breast cancer: a nationwide study

Preclinical study

Bazedoxifene is a novel IL-6/GP130 inhibitor for treating triple-negative breast cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits